Primary Objectives:
Secondary Objectives
Part C:
High grade ovarian cancer:
Part D:
Cohort D1 (PRO1184+carboplatin):
Cohort D2 (PRO1184+bevacizumab):
-Patients must have platinum-resistant/refractory ovarian cancer
Cohort D3 (PRO1184+pembrolizumab):